UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
32.10
+2.31 (7.75%)
Nov 19, 2026, 1:58 PM EST - Market open
UroGen Pharma Employees
UroGen Pharma had 300 employees as of September 30, 2026. The number of employees increased by 13 or 4.53% compared to the same quarter last year. That makes UroGen Pharma the 23,904th largest employer in the world and 3,052nd in the United States.
Employees
300
Change (1Y)
13
Growth (1Y)
4.53%
Revenue / Employee
$834,177
Profits / Employee
-$219,170
Market Cap
1.57B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2026 | 300 | 13 | 4.53% | 300 | 0 |
| Jun 30, 2026 | 300 | 47 | 18.58% | 300 | 0 |
| Mar 31, 2026 | 298 | 64 | 27.35% | 298 | 0 |
| Dec 31, 2025 | 291 | 56 | 23.83% | 291 | 0 |
| Sep 30, 2025 | 287 | 70 | 32.26% | 287 | 0 |
| Jun 30, 2025 | 253 | 50 | 24.63% | 253 | 0 |
| Mar 31, 2025 | 234 | 30 | 14.71% | 234 | 0 |
| Dec 31, 2024 | 235 | 34 | 16.92% | 235 | 0 |
| Sep 30, 2024 | 217 | 25 | 13.02% | 217 | 0 |
| Jun 30, 2024 | 203 | 10 | 5.18% | 203 | 0 |
| Mar 31, 2024 | 204 | 10 | 5.15% | 204 | 0 |
| Dec 31, 2023 | 201 | 1 | 0.50% | 198 | 3 |
| Sep 30, 2023 | 192 | -3 | -1.54% | 192 | 0 |
| Jun 30, 2023 | 193 | -8 | -3.98% | 193 | 0 |
| Mar 31, 2023 | 194 | 2 | 1.04% | 194 | 0 |
| Dec 31, 2022 | 200 | 5 | 2.56% | 200 | 0 |
| Sep 30, 2022 | 195 | -3 | -1.52% | 195 | 0 |
| Jun 30, 2022 | 201 | 11 | 5.79% | 201 | 0 |
| Mar 31, 2022 | 192 | 2 | 1.05% | 192 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immunocore Holdings | 524 |
| Nurix Therapeutics | 317 |
| Nuvation Bio | 310 |
| uniQure | 221 |
| Precigen | 160 |
| Rapport Therapeutics | 84 |
| Korsana Biosciences | 19 |
| Damora Therapeutics | 7 |
URGN News
- 9 days ago - UroGen Pharma Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 14 days ago - UroGen Pharma price target lowered to $62 from $65 at Ladenburg - TheFly
- 14 days ago - UroGen Pharma price target lowered to $56 from $58 at Guggenheim - TheFly
- 15 days ago - UroGen Pharma Earnings Call Transcript: Q3 2026 - Transcripts
- 15 days ago - UroGen Pharma Earnings release: Q3 2026 - Filings
- 15 days ago - UroGen Pharma Quarterly report: Q3 2026 - Filings
- 15 days ago - UroGen Pharma reports Q3 EPS (3c), consensus 10c - TheFly
- 15 days ago - UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights - GlobeNewsWire